3.54k followers • 15 symbols +0.20% Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Rising bond yields are creating new opportunities for income-seeking investors, but some companies are sweetening their payouts as well.
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
The company announced third-quarter 2018 earnings and a pipeline update, but investors weren't happy with results from an important trial announced in early December.
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bristol-Myers Squibb (BMY) closed the most recent trading day at $53.08, moving -0.32% from the previous trading session.
The drug maker is down by a double-digit percentage so far this year, but BMO Capital Markets analyst Alex Arfaei lifted his rating to Outperform from Market Perform.
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron Corporation (NASDAQ:GERN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is GERN will Read More...
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
HealthEquity's (HQY) impressive results in Q3 can be attributed to solid growth in HSA Members. Its bullish guidance for fiscal 2019 further raises investors' optimism on the stock.
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
Joshua Levine became the CEO of Accuray Incorporated (NASDAQ:ARAY) in 2012. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider Read More...